截至发稿，南模生物市值为45亿元。 每经头条（nbdtoutiao）——能给主人"打电话"的宠物智能手机也来了！宠物产业3000亿元市场大爆 发，行业上市公司"涨"声一片 （记者 王晓波） 每经AI快讯，南模生物（SH 688265，收盘价：57.33元）8月26日晚间发布公告称，公司第三届第二十 三次董事会会议于2025年8月25日以现场结合通讯方式召开。会议审议了《关于控股股东提请召开临时 股东大会的议案》等文件。 2024年1至12月份，南模生物的营业收入构成为：科学研究和技术服务业占比99.28%，其他业务占比 0.72%。 ...

证券代码：688265 证券简称：南模生物 公告编号：2025-050 上海南方模式生物科技股份有限公司 第三届董事会第二十三次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 有董事对本次董事会审议的议案投反对票、弃权票。 一、董事会会议召开情况 上海南方模式生物科技股份有限公司（以下简称"公司"）第三届董事会第二 十三次会议于 2025 年 8 月 25 日以现场结合通讯方式召开。本次会议的通知已于 2025 年 8 月 21 日以电子邮件方式送达全体董事。本次会议由董事长费俭先生召 集并主持，应参会董事 9 人，实际出席董事 9 人，其中独立董事 3 人，公司监事、 高级管理人员列席了会议。本次会议的召集、召开符合《中华人民共和国公司法》 等法律法规及《公司章程》的相关规定。 二、董事会会议审议情况 1、审议通过《关于控股股东提请召开临时股东大会的议案》 2025年8月16日，公司收到控股股东上海砥石企业管理咨询有限公司（以下 简称"砥石咨询"）发来的《关于提请召开上海南方模式生物科技股份 ...

南模生物8月21日股价报60.10元，较前一交易日下跌1.40元，跌幅2.28%。当日开盘价为62.00元，最高 触及62.28元，最低下探至59.70元，成交量为19711手，成交金额1.19亿元。 公开信息显示，南模生物股东方近期实施了股份增持。8月20日有消息称，包括南模生物在内的多家医 药上市公司股东进行了股份回购或增持操作。 8月21日南模生物主力资金净流出656.50万元，占流通市值比例为0.14%。近五个交易日累计主力资金净 流出1324.74万元，占流通市值比例为0.28%。 风险提示：股市有风险，投资需谨慎。 南模生物属于生物制品行业，主营业务为模式动物与基因修饰动物模型的研发、生产及销售。公司产品 主要应用于生命科学基础研究、药物研发等领域。 ...

| 代码 | 名称 | 收盘价 | 涨跌幅 | 成交量(手) | 成交额(元) | | --- | --- | --- | --- | --- | --- | | 688265 | 南模生物 | 65.00 | -8.32% | 4.65万 | 3.07亿 | | 002173 | 创新医疗 | 24.84 | -6.97% | 147.80万 | 37.90亿 | | 652509 | 药明康德 | 90.26 | -6.93% | 131.17万 | 123.20亿 | | 300683 | 海特生物 | 54.33 | -4.58% | 15.33万 | 8.89亿 | | 688046 | 药康生物 | 18.08 | -4.49% | 6.06万 | 1.12亿 | | 301096 | 百诚医药 | 54.66 | -4.31% | 12.34万 | 6.85亿 | | 002622 | 皓宸医疗 | 3.60 | -3.74% | 80.54万 | 2.91亿 | | 688202 | 美迪西 | 64.23 | -3.70% | 10.89万 | 7.38亿 | | 300347 | 泰格医药 ...

Group 1 - The A-share market has seen a decline in several biopharmaceutical stocks, with notable drops including Nanmo Bio down 9%, Shanghai Yizhong down over 7%, and Nuocheng Jianhua down over 5% [1] - Other companies experiencing declines include Yangguang Nuohuo and Guangshengtang down over 4%, and Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio down over 3% [1] Group 2 - Specific stock performance includes: - Nanmo Bio (688265) down 9.06% with a market cap of 5.027 billion and a year-to-date increase of 178.89% - Shanghai Yizhong (688091) down 7.23% with a market cap of 15.7 billion and a year-to-date increase of 89.98% - Nuocheng Jianhua (688428) down 5.25% with a market cap of 56 billion and a year-to-date increase of 158.55% - Yangguang Nuohuo (688621) down 4.57% with a market cap of 8.727 billion and a year-to-date increase of 107.29% - Guangshengtang (300436) down 4.26% with a market cap of 26.3 billion and a year-to-date increase of 404.68% [2]

Group 1 - A-share market sees weakness in certain biopharmaceutical stocks, with notable declines in several companies [1] - Nanmo Bio falls by 9%, while Shanghai Yizhong drops over 7% [1] - Nocare Health declines by over 5%, and Sunshine Nuohe and Guangshengtang both decrease by over 4% [1] - Haichuang Pharmaceutical, Baicheng Pharmaceutical, Yaokang Bio, and Qianyan Bio all experience declines of over 3% [1]

Group 1 - The company received a request from its controlling shareholder, Shanghai Tishi Enterprise Management Consulting Co., Ltd., to convene an extraordinary general meeting of shareholders to discuss the re-election of the board of directors [1][2] - The request is based on the expiration of the current board's term on May 19, 2025, and aims to ensure proper corporate governance and the company's stable operation [1][2] - The company is required to respond to the request within 10 days, indicating whether it agrees or disagrees to hold the extraordinary general meeting [2] Group 2 - The controlling shareholder holds more than 10% of the company's shares, which allows them to request the meeting under relevant laws and regulations [2] - The extraordinary general meeting is proposed to be held within 30 days from the date of the request [2] - The company will disclose all relevant information in accordance with legal requirements and designated media [2][3]

证券代码：688265 证券简称：南模生物 公告编号：2025-049 一、股东提议召开股东大会的情况 "上海南方模式生物科技股份有限公司董事会： 鉴于上海南方模式生物科技股份有限公司（"公司"）第三届董事会任期已 于 2025 年 5 月 19 日届满，为尽快规范公司治理、保障公司治理与经营稳定、维 护公司依法合规运作、促进公司持续健康发展，上海砥石企业管理咨询有限公司 （"我司"）作为公司第一大股东且作为持有公司 10%以上股份的股东，根据《中 华人民共和国公司法》《中华人民共和国证券法》《上市公司股东大会规则》《上 海证券交易所股票上市规则》《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等法律、行政法规、规范性文件以及《上海南方模式生物科 技股份有限公司章程》《上海南方模式生物科技股份有限公司股东大会议事规则》 的相关规定，现向公司董事会发出本函（"《提请函》"），提议公司董事会召 集召开公司临时股东大会（暨公司 2025 年第二次临时股东大会，若召集召开公 司临时股东大会时会议届次发生变化的，则相应调整会议届次，不影响本函所列 议案的审议）并审议公司董事会换届选举相关议案。 上海南 ...

Investment Rating - The report assigns an "Overweight" rating to the pharmaceutical and biotechnology industry, indicating that the industry index is expected to outperform the CSI 300 index by 10% or more over the next six months [2][34]. Core Insights - The pharmaceutical and biotechnology sector saw an overall increase of 3.08% from August 11 to August 15, 2025, ranking 10th among 31 industries and outperforming the CSI 300 index by 0.71 percentage points. Year-to-date, the sector has risen by 25.02%, ranking 4th among the industries and outperforming the CSI 300 index by 18.22 percentage points [4][14]. - The current PE valuation for the pharmaceutical and biotechnology sector is 31.31 times, which is at the historical median level, with a valuation premium of 145% compared to the CSI 300 index [4][20]. - Key sub-sectors that performed well include medical services, chemical pharmaceuticals, and medical devices, with respective increases of 6.60%, 3.80%, and 2.22% [4][13]. Market Performance - The pharmaceutical and biotechnology sector's performance for the week of August 11-15, 2025, showed a 3.08% increase, ranking 10th among 31 industries, and outperforming the CSI 300 index by 0.71 percentage points. Year-to-date, the sector has increased by 25.02%, ranking 4th among industries and outperforming the CSI 300 index by 18.22 percentage points [4][14]. - The top three performing sub-sectors were medical services, chemical pharmaceuticals, and medical devices, with increases of 6.60%, 3.80%, and 2.22% respectively [4][13]. Industry News - On August 12, 2025, the National Medical Insurance Administration announced the preliminary review list of drugs for the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Directory, with 534 drugs passing the basic medical insurance review and 121 passing the commercial insurance review [5][28]. - On August 15, 2025, the National Medical Insurance Administration issued a temporary management method for disease-based payment, aimed at reforming the payment method primarily based on disease categories [5][29]. - On August 15, 2025, Novo Nordisk announced that the supplemental new drug application for semaglutide (Wegovy) was approved by the FDA for treating metabolic dysfunction-associated fatty liver disease (MASH) in patients with mid-to-late stage liver fibrosis [5][30]. Investment Recommendations - The report suggests that the pharmaceutical and biotechnology sector continues to strengthen after a slight adjustment, outperforming the broader market index. It recommends focusing on investment opportunities in innovative drugs, CXO, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [6][31]. - Recommended stocks include Betta Pharmaceuticals, Teva Pharmaceutical, Kaili Medical, Anjies, and Huaxia Eye Hospital, while stocks to watch include Kelun Pharmaceutical, Qianhong Pharmaceutical, Haier Biomedical, Kangtai Biological, and Baipusais [6][31].

● 公司股价短期波动幅度较大，敬请广大投资者注意二级市场交易风险，审慎决策，理性投资。 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688265 证券简称：南模生物 公告编号：2025-048 上海南方模式生物科技股份有限公司 股票交易异常波动公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示 ● 上海南方模式生物科技股份有限公司（以下简称"公司"）股票连续两个交易日内（2025年8月14日、8 月15日）收盘价格涨幅偏离值累计超过30%，根据《上海证券交易所交易规则》《上海证券交易所科创 板股票异常交易实时监控细则》的有关规定，属于股票交易异常波动的情形。 ● 经公司自查并书面发函向公司控股股东、实际控制人核实，截至本公告披露日，不存在应披露而未披 露的重大信息。 经公司自查，并向控股股东、实际控制人书面发函后确认：截至本公告披露日，公司及控股股东、实际 控制人不存在正在筹划并购重组、股份发行、债务重组、业务重组、资产剥离和资产注入等重大事项， 亦不存在其他应披露而未披露的重大信息。 一、 ...